An investigational drug for advanced multiple myeloma met both of its primary endpoints in a late-stage trial, producing responses in 74 percent of patients whose disease had already resisted three major classes of treatment. Patients receiving standard available therapies responded at 45.7 percent.
The drug, etentamig, also reduced the risk of disease progression or death by 60 percent. AbbVie reported the topline results from its 393-patient Phase 3 CERVINO study in a company announcement, and the effect was large enough that an independent data monitoring committee recommended unblinding the trial at the first planned interim efficacy analysis.
For patients living with relapsed or refractory multiple myeloma, and for the families managing their care, the more consequential detail may be how the drug is given. It is administered once every four weeks from initiation after a single step-up dose, a schedule the company argues could allow treatment outside specialized cancer centers.
Seventy-Four Percent Responded, Against Forty-Six on Standard Care
The trial enrolled patients with triple-class exposed disease, meaning their myeloma had already been treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Participants had received a median of three prior lines of therapy.
At a median follow-up of 11.4 months, the objective response rate was 74.0 percent for etentamig versus 45.7 percent for investigator's choice of standard available therapies. The progression-free survival hazard ratio was 0.40, corresponding to a 60 percent reduction in risk, and the benefit appeared across all prespecified subgroups evaluated.
Twelve-month overall survival was 87.9 percent for etentamig and 72.0 percent for standard care, with a hazard ratio of 0.48. AbbVie notes that the prespecified efficacy boundary for overall survival was not crossed at the data cutoff, which means that particular result should be read as encouraging rather than established.
The Dosing Schedule Is the Practical Story
Etentamig belongs to a class called BCMA-directed bispecific T-cell engagers, which link a patient's own T cells to myeloma cells. Drugs in this class and CAR-T cell therapies have changed myeloma treatment, but their adoption remains limited by side effects and by the monitoring infrastructure they require.
The most feared of those side effects is cytokine release syndrome, an inflammatory reaction that can cause fever, low blood pressure, and organ stress. In CERVINO, among patients who received a single step-up dose, cytokine release syndrome occurred in 28.3 percent and was predominantly grade 1, the mildest category, at 23.9 percent. No grade 3 or higher events were reported.
One patient experienced grade 1 immune effector cell-associated neurotoxicity syndrome, with no grade 2 or higher events. Grade 3 or 4 infections occurred in 27.7 percent of etentamig patients and 19.2 percent of those on standard therapy, a difference consistent with known infection risks in this drug class. Fatal infections were less common with etentamig at 1.5 percent than with standard care at 3.1 percent. Discontinuations related to treatment-emergent adverse events were 3.6 percent against 9.6 percent.
Peter Voorhees, chief of the plasma cell disorders division at Atrium Health Levine Cancer Institute and an investigator on the trial, framed the access question directly. The findings, he said, support the drug as a BCMA-targeted bispecific option with "the potential to provide access across a range of treatment settings."
Company Data, Interim Analysis, and What Is Not Yet Proven
Several limitations belong near the top rather than buried. These are topline results announced by the manufacturer, not a peer-reviewed publication. Full data are scheduled for a plenary session at the International Myeloma Society Annual Meeting in Glasgow, Scotland, later this month.
The trial was open-label, meaning patients and investigators knew which treatment was being given. That design is common in this setting because the comparison arm involves multiple different regimens, but it can influence subjective assessments.
This was also the first planned interim efficacy analysis. Interim results with wide separation between arms sometimes moderate as follow-up lengthens, and median follow-up here is under a year in a disease where patients can live for years after relapse.
Etentamig is investigational. It has not been approved by the Food and Drug Administration or any other regulator, and AbbVie says it plans to discuss the results with global regulatory authorities to determine next steps. No patient can obtain it outside a clinical trial today, and the study is listed on ClinicalTrials.gov. An earlier first-in-human study of the same molecule was published in 2022.
The comparison arm also deserves a note. Patients on standard care received one of three combination regimens chosen by their physician: carfilzomib plus dexamethasone, elotuzumab plus pomalidomide and dexamethasone, or selinexor plus bortezomib and dexamethasone. That reflects real practice but makes the control group less uniform than a single-drug comparison would be.
Community Clinics Could Become the Point of Access
Multiple myeloma is a cancer of plasma cells in the bone marrow. It is generally treatable but not curable, and patients typically move through successive lines of therapy as the disease returns. Patients who have exhausted the three main drug classes have historically had increasingly limited options.
Where a patient lives has practical bearing on what they can receive. Bispecific antibodies and CAR-T therapies have concentrated at medical centers that can manage cytokine release syndrome and provide the required monitoring, which researchers have identified as a barrier to integrating these drugs into community practice. Patients in smaller cities and rural areas often face travel, lodging costs, and time away from work to access them.
A monthly injection with predominantly low-grade cytokine release syndrome is the kind of profile that could shift some of that care closer to home, if the results hold and if regulators agree. That is a meaningful if, and it will not be settled by a press release.
Patients and caregivers with questions about whether a trial is appropriate should raise them with a treating hematologist or oncologist. Nothing in these results changes current treatment recommendations, and no one should alter an existing regimen based on them.
Key Questions Answered
What is etentamig? An investigational second-generation bispecific antibody that links immune T cells to a protein called BCMA found on myeloma cells. It is not approved by any regulator.
What did the trial show? In 393 patients, 74.0 percent responded to etentamig compared with 45.7 percent on standard therapies, and the risk of disease progression or death fell by 60 percent.
Who was studied? Patients with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy, including three major drug classes, with a median of three prior lines.
How serious were the side effects? Cytokine release syndrome occurred in 28.3 percent of patients receiving a single step-up dose and was mostly the mildest grade, with no grade 3 or higher cases. Serious infections were more common than with standard care.
Are these results peer reviewed? No. These are topline results announced by the manufacturer. Full data are scheduled for presentation at a myeloma conference later this month.
When could patients get this drug? No timeline exists. The company says it will discuss next steps with regulators. Approval would require a submission and review, and the drug remains available only through clinical trials.
Should any patient change treatment because of this? No. Current treatment recommendations are unchanged. Questions about trial eligibility should go to a treating hematologist or oncologist.
